SEARCH

SEARCH BY CITATION

References

  • 1
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer (Chinese Version), 1st edn. EMD, Scintific Communication Group, Beijing 2009.
  • 2
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer. NCCN, Inc. Fort Washington 2009.
  • 3
    D'Addario G, Felip E, On Behalf of the ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): iv68iv70.
  • 4
    Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 223746.
  • 5
    Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: result from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 152737.
  • 6
    Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 180918.
  • 7
    Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 214958.
  • 8
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 12332.